|
|
 |
|
Viewing report
|
|
|
|
Bipolar Disorder - Global Strategic Business Report
Global Industry Analysts, Inc., June 2010, Pages: 565
This report analyzes the worldwide markets for Bipolar Disorder in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through 2015. The report profiles 53 companies including many key and niche players such as Abbott Laboratories, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Cephalon, Inc., Dainippon Sumitomo Pharma Co. Ltd., Eli Lilly and Company, Forest Laboratories, Inc., Gedeon Richter PLC, GlaxoSmithKline PLC, H. Lundbeck A/S, Janssen Pharmaceutica, Inc., Parent Company Profile - Johnson and Johnson Merck & Co., Inc., Otsuka America Pharmaceutical Inc., Pfizer, Inc., Repligen Corporation, and Validus Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
Customers who bought this item also bought
CNS Therapeutics - Global Strategic Business Report
Anti-Migraine Drugs - Global Strategic Business Report
Anxiety Disorders - Global Strategic Business Report
Prescription Drugs - Global Strategic Business Report
Anti-Hypertensive Drugs - Global Strategic Business Report
Opthalmic Pharmaceutical Drugs - Global Strategic Business Report
Antibacterial Drugs - Global Strategic Business Report
ADHD Therapeutics - Global Strategic Business Report
Glaucoma Pharmaceuticals - Global Strategic Business Report
Anti-Infectives - Global Strategic Business Report
|
|
|
|
